Arctic Bioscience (ABS) Q1 2026 TU earnings summary

Executive summary

• Achieved 78% year-over-year revenue growth in Q1 2026, reaching NOK 11.9 million, the highest first-quarter revenues to date, driven by Nutra segment performance and robust order intake.

• HRO350 demonstrated significant reduction in systemic inflammation in the HeROPA trial, fueling ongoing pharma partner discussions and positive feedback at BIO Europe.

• Opened a ROMEGA® concept store in Hainan, China, and expanded B2C and B2B Nutra sales across Europe, Americas, and APAC.

• Secured NOK 15 million in new long-term financing to support operations and strengthen liquidity.

• Positive gross margin development, reaching 34.3% in Q1 2026, up 7.3 percentage points from Q1 2025.

Financial highlights

• Q1 2026 sales revenue reached NOK 11.9 million, up from NOK 6.7 million in Q1 2025.

• Gross margin improved to 34.3% from 27.0% year-over-year.

• Adjusted EBITDA loss narrowed to NOK -6.5 million from NOK -9.1 million in Q1 2025, reflecting cost reductions.

• American market accounted for 51% of Q1 2026 revenues, with revenue increasing from NOK 0.6 million to NOK 6.0 million year-over-year.

• Available liquidity at quarter-end was NOK 0.3 million, with NOK 15 million financing secured post-quarter.

Outlook and guidance

• Expectation of continued Nutra revenue growth in 2026, supported by strong Q1 sales and order outlook.

• Multiple new partner product launches anticipated in various regions throughout 2026.

• Further HRO350 development to be funded through partnerships or project-specific funding.

• Data from HeROPA trial to be published and presented in 2026, increasing visibility.

• Ongoing cost and liquidity discipline, with board monitoring additional measures.